TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media

Necrotizing Autoimmune Myositis Market, Global Outlook and Forecast 2023-2030

Necrotizing Autoimmune Myositis Market, Global Outlook and Forecast 2023-2030

  • Category:Life Sciences
  • Published on : 30 January 2023
  • Pages :69
  • Formats:
  • Report Code:SMR-7547212

This report contains market size and forecasts of Necrotizing Autoimmune Myositis in Global, including the following market information:
Global Necrotizing Autoimmune Myositis Market Revenue, 2018-2023, 2023-2030, ($ millions)
Global top five companies in 2022 (%)
The global Necrotizing Autoimmune Myositis market was valued at US$ million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period 2023-2030.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million by 2030.
Steroids Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Necrotizing Autoimmune Myositis include GlaxoSmithKline plc, Dr. Reddy's Laboratories, Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.), Hetero Drugs Limited, AbbVie Inc., Teva Pharmaceutical Industries and Novartis AG, etc. In 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Necrotizing Autoimmune Myositis companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Necrotizing Autoimmune Myositis Market, by Type, 2018-2023, 2023-2030 ($ millions)
Global Necrotizing Autoimmune Myositis Market Segment Percentages, by Type, 2022 (%)
Steroids
Immunosuppressant
Others
Global Necrotizing Autoimmune Myositis Market, by Application, 2018-2023, 2023-2030 ($ millions)
Global Necrotizing Autoimmune Myositis Market Segment Percentages, by Application, 2022 (%)
Hospital
Clinic
Others
Global Necrotizing Autoimmune Myositis Market, By Region and Country, 2018-2023, 2023-2030 ($ Millions)
Global Necrotizing Autoimmune Myositis Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Necrotizing Autoimmune Myositis revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Necrotizing Autoimmune Myositis revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
GlaxoSmithKline plc
Dr. Reddy's Laboratories
Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.)
Hetero Drugs Limited
AbbVie Inc.
Teva Pharmaceutical Industries
Novartis AG

TABLE OF CONTENTS

1 Introduction to Research & Analysis Reports
1.1 Necrotizing Autoimmune Myositis Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Necrotizing Autoimmune Myositis Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Necrotizing Autoimmune Myositis Overall Market Size
2.1 Global Necrotizing Autoimmune Myositis Market Size: 2022 VS 2030
2.2 Global Necrotizing Autoimmune Myositis Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Necrotizing Autoimmune Myositis Players in Global Market
3.2 Top Global Necrotizing Autoimmune Myositis Companies Ranked by Revenue
3.3 Global Necrotizing Autoimmune Myositis Revenue by Companies
3.4 Top 3 and Top 5 Necrotizing Autoimmune Myositis Companies in Global Market, by Revenue in 2022
3.5 Global Companies Necrotizing Autoimmune Myositis Product Type
3.6 Tier 1, Tier 2 and Tier 3 Necrotizing Autoimmune Myositis Players in Global Market
3.6.1 List of Global Tier 1 Necrotizing Autoimmune Myositis Companies
3.6.2 List of Global Tier 2 and Tier 3 Necrotizing Autoimmune Myositis Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Necrotizing Autoimmune Myositis Market Size Markets, 2022 & 2030
4.1.2 Steroids
4.1.3 Immunosuppressant
4.1.4 Others
4.2 By Type - Global Necrotizing Autoimmune Myositis Revenue & Forecasts
4.2.1 By Type - Global Necrotizing Autoimmune Myositis Revenue, 2018-2023
4.2.2 By Type - Global Necrotizing Autoimmune Myositis Revenue, 2023-2030
4.2.3 By Type - Global Necrotizing Autoimmune Myositis Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Necrotizing Autoimmune Myositis Market Size, 2022 & 2030
5.1.2 Hospital
5.1.3 Clinic
5.1.4 Others
5.2 By Application - Global Necrotizing Autoimmune Myositis Revenue & Forecasts
5.2.1 By Application - Global Necrotizing Autoimmune Myositis Revenue, 2018-2023
5.2.2 By Application - Global Necrotizing Autoimmune Myositis Revenue, 2023-2030
5.2.3 By Application - Global Necrotizing Autoimmune Myositis Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Necrotizing Autoimmune Myositis Market Size, 2022 & 2030
6.2 By Region - Global Necrotizing Autoimmune Myositis Revenue & Forecasts
6.2.1 By Region - Global Necrotizing Autoimmune Myositis Revenue, 2018-2023
6.2.2 By Region - Global Necrotizing Autoimmune Myositis Revenue, 2023-2030
6.2.3 By Region - Global Necrotizing Autoimmune Myositis Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Necrotizing Autoimmune Myositis Revenue, 2018-2030
6.3.2 US Necrotizing Autoimmune Myositis Market Size, 2018-2030
6.3.3 Canada Necrotizing Autoimmune Myositis Market Size, 2018-2030
6.3.4 Mexico Necrotizing Autoimmune Myositis Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Necrotizing Autoimmune Myositis Revenue, 2018-2030
6.4.2 Germany Necrotizing Autoimmune Myositis Market Size, 2018-2030
6.4.3 France Necrotizing Autoimmune Myositis Market Size, 2018-2030
6.4.4 U.K. Necrotizing Autoimmune Myositis Market Size, 2018-2030
6.4.5 Italy Necrotizing Autoimmune Myositis Market Size, 2018-2030
6.4.6 Russia Necrotizing Autoimmune Myositis Market Size, 2018-2030
6.4.7 Nordic Countries Necrotizing Autoimmune Myositis Market Size, 2018-2030
6.4.8 Benelux Necrotizing Autoimmune Myositis Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Necrotizing Autoimmune Myositis Revenue, 2018-2030
6.5.2 China Necrotizing Autoimmune Myositis Market Size, 2018-2030
6.5.3 Japan Necrotizing Autoimmune Myositis Market Size, 2018-2030
6.5.4 South Korea Necrotizing Autoimmune Myositis Market Size, 2018-2030
6.5.5 Southeast Asia Necrotizing Autoimmune Myositis Market Size, 2018-2030
6.5.6 India Necrotizing Autoimmune Myositis Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Necrotizing Autoimmune Myositis Revenue, 2018-2030
6.6.2 Brazil Necrotizing Autoimmune Myositis Market Size, 2018-2030
6.6.3 Argentina Necrotizing Autoimmune Myositis Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Necrotizing Autoimmune Myositis Revenue, 2018-2030
6.7.2 Turkey Necrotizing Autoimmune Myositis Market Size, 2018-2030
6.7.3 Israel Necrotizing Autoimmune Myositis Market Size, 2018-2030
6.7.4 Saudi Arabia Necrotizing Autoimmune Myositis Market Size, 2018-2030
6.7.5 UAE Necrotizing Autoimmune Myositis Market Size, 2018-2030
7 Players Profiles
7.1 GlaxoSmithKline plc
7.1.1 GlaxoSmithKline plc Corporate Summary
7.1.2 GlaxoSmithKline plc Business Overview
7.1.3 GlaxoSmithKline plc Necrotizing Autoimmune Myositis Major Product Offerings
7.1.4 GlaxoSmithKline plc Necrotizing Autoimmune Myositis Revenue in Global Market (2018-2023)
7.1.5 GlaxoSmithKline plc Key News
7.2 Dr. Reddy's Laboratories
7.2.1 Dr. Reddy's Laboratories Corporate Summary
7.2.2 Dr. Reddy's Laboratories Business Overview
7.2.3 Dr. Reddy's Laboratories Necrotizing Autoimmune Myositis Major Product Offerings
7.2.4 Dr. Reddy's Laboratories Necrotizing Autoimmune Myositis Revenue in Global Market (2018-2023)
7.2.5 Dr. Reddy's Laboratories Key News
7.3 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.)
7.3.1 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Corporate Summary
7.3.2 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Business Overview
7.3.3 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Necrotizing Autoimmune Myositis Major Product Offerings
7.3.4 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Necrotizing Autoimmune Myositis Revenue in Global Market (2018-2023)
7.3.5 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Key News
7.4 Hetero Drugs Limited
7.4.1 Hetero Drugs Limited Corporate Summary
7.4.2 Hetero Drugs Limited Business Overview
7.4.3 Hetero Drugs Limited Necrotizing Autoimmune Myositis Major Product Offerings
7.4.4 Hetero Drugs Limited Necrotizing Autoimmune Myositis Revenue in Global Market (2018-2023)
7.4.5 Hetero Drugs Limited Key News
7.5 AbbVie Inc.
7.5.1 AbbVie Inc. Corporate Summary
7.5.2 AbbVie Inc. Business Overview
7.5.3 AbbVie Inc. Necrotizing Autoimmune Myositis Major Product Offerings
7.5.4 AbbVie Inc. Necrotizing Autoimmune Myositis Revenue in Global Market (2018-2023)
7.5.5 AbbVie Inc. Key News
7.6 Teva Pharmaceutical Industries
7.6.1 Teva Pharmaceutical Industries Corporate Summary
7.6.2 Teva Pharmaceutical Industries Business Overview
7.6.3 Teva Pharmaceutical Industries Necrotizing Autoimmune Myositis Major Product Offerings
7.6.4 Teva Pharmaceutical Industries Necrotizing Autoimmune Myositis Revenue in Global Market (2018-2023)
7.6.5 Teva Pharmaceutical Industries Key News
7.7 Novartis AG
7.7.1 Novartis AG Corporate Summary
7.7.2 Novartis AG Business Overview
7.7.3 Novartis AG Necrotizing Autoimmune Myositis Major Product Offerings
7.7.4 Novartis AG Necrotizing Autoimmune Myositis Revenue in Global Market (2018-2023)
7.7.5 Novartis AG Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

LIST OF TABLES & FIGURES

List of Tables
Table 1. Necrotizing Autoimmune Myositis Market Opportunities & Trends in Global Market
Table 2. Necrotizing Autoimmune Myositis Market Drivers in Global Market
Table 3. Necrotizing Autoimmune Myositis Market Restraints in Global Market
Table 4. Key Players of Necrotizing Autoimmune Myositis in Global Market
Table 5. Top Necrotizing Autoimmune Myositis Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Necrotizing Autoimmune Myositis Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Necrotizing Autoimmune Myositis Revenue Share by Companies, 2018-2023
Table 8. Global Companies Necrotizing Autoimmune Myositis Product Type
Table 9. List of Global Tier 1 Necrotizing Autoimmune Myositis Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Necrotizing Autoimmune Myositis Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Necrotizing Autoimmune Myositis Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Necrotizing Autoimmune Myositis Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Necrotizing Autoimmune Myositis Revenue in Global (US$, Mn), 2023-2030
Table 14. By Application ? Global Necrotizing Autoimmune Myositis Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Necrotizing Autoimmune Myositis Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Necrotizing Autoimmune Myositis Revenue in Global (US$, Mn), 2023-2030
Table 17. By Region ? Global Necrotizing Autoimmune Myositis Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Necrotizing Autoimmune Myositis Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Necrotizing Autoimmune Myositis Revenue (US$, Mn), 2023-2030
Table 20. By Country - North America Necrotizing Autoimmune Myositis Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Necrotizing Autoimmune Myositis Revenue, (US$, Mn), 2023-2030
Table 22. By Country - Europe Necrotizing Autoimmune Myositis Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Necrotizing Autoimmune Myositis Revenue, (US$, Mn), 2023-2030
Table 24. By Region - Asia Necrotizing Autoimmune Myositis Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Necrotizing Autoimmune Myositis Revenue, (US$, Mn), 2023-2030
Table 26. By Country - South America Necrotizing Autoimmune Myositis Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Necrotizing Autoimmune Myositis Revenue, (US$, Mn), 2023-2030
Table 28. By Country - Middle East & Africa Necrotizing Autoimmune Myositis Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Necrotizing Autoimmune Myositis Revenue, (US$, Mn), 2023-2030
Table 30. GlaxoSmithKline plc Corporate Summary
Table 31. GlaxoSmithKline plc Necrotizing Autoimmune Myositis Product Offerings
Table 32. GlaxoSmithKline plc Necrotizing Autoimmune Myositis Revenue (US$, Mn), (2018-2023)
Table 33. Dr. Reddy's Laboratories Corporate Summary
Table 34. Dr. Reddy's Laboratories Necrotizing Autoimmune Myositis Product Offerings
Table 35. Dr. Reddy's Laboratories Necrotizing Autoimmune Myositis Revenue (US$, Mn), (2018-2023)
Table 36. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Corporate Summary
Table 37. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Necrotizing Autoimmune Myositis Product Offerings
Table 38. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Necrotizing Autoimmune Myositis Revenue (US$, Mn), (2018-2023)
Table 39. Hetero Drugs Limited Corporate Summary
Table 40. Hetero Drugs Limited Necrotizing Autoimmune Myositis Product Offerings
Table 41. Hetero Drugs Limited Necrotizing Autoimmune Myositis Revenue (US$, Mn), (2018-2023)
Table 42. AbbVie Inc. Corporate Summary
Table 43. AbbVie Inc. Necrotizing Autoimmune Myositis Product Offerings
Table 44. AbbVie Inc. Necrotizing Autoimmune Myositis Revenue (US$, Mn), (2018-2023)
Table 45. Teva Pharmaceutical Industries Corporate Summary
Table 46. Teva Pharmaceutical Industries Necrotizing Autoimmune Myositis Product Offerings
Table 47. Teva Pharmaceutical Industries Necrotizing Autoimmune Myositis Revenue (US$, Mn), (2018-2023)
Table 48. Novartis AG Corporate Summary
Table 49. Novartis AG Necrotizing Autoimmune Myositis Product Offerings
Table 50. Novartis AG Necrotizing Autoimmune Myositis Revenue (US$, Mn), (2018-2023)
List of Figures
Figure 1. Necrotizing Autoimmune Myositis Segment by Type in 2022
Figure 2. Necrotizing Autoimmune Myositis Segment by Application in 2022
Figure 3. Global Necrotizing Autoimmune Myositis Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Necrotizing Autoimmune Myositis Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Necrotizing Autoimmune Myositis Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Necrotizing Autoimmune Myositis Revenue in 2022
Figure 8. By Type - Global Necrotizing Autoimmune Myositis Revenue Market Share, 2018-2030
Figure 9. By Application - Global Necrotizing Autoimmune Myositis Revenue Market Share, 2018-2030
Figure 10. By Region - Global Necrotizing Autoimmune Myositis Revenue Market Share, 2018-2030
Figure 11. By Country - North America Necrotizing Autoimmune Myositis Revenue Market Share, 2018-2030
Figure 12. US Necrotizing Autoimmune Myositis Revenue, (US$, Mn), 2018-2030
Figure 13. Canada Necrotizing Autoimmune Myositis Revenue, (US$, Mn), 2018-2030
Figure 14. Mexico Necrotizing Autoimmune Myositis Revenue, (US$, Mn), 2018-2030
Figure 15. By Country - Europe Necrotizing Autoimmune Myositis Revenue Market Share, 2018-2030
Figure 16. Germany Necrotizing Autoimmune Myositis Revenue, (US$, Mn), 2018-2030
Figure 17. France Necrotizing Autoimmune Myositis Revenue, (US$, Mn), 2018-2030
Figure 18. U.K. Necrotizing Autoimmune Myositis Revenue, (US$, Mn), 2018-2030
Figure 19. Italy Necrotizing Autoimmune Myositis Revenue, (US$, Mn), 2018-2030
Figure 20. Russia Necrotizing Autoimmune Myositis Revenue, (US$, Mn), 2018-2030
Figure 21. Nordic Countries Necrotizing Autoimmune Myositis Revenue, (US$, Mn), 2018-2030
Figure 22. Benelux Necrotizing Autoimmune Myositis Revenue, (US$, Mn), 2018-2030
Figure 23. By Region - Asia Necrotizing Autoimmune Myositis Revenue Market Share, 2018-2030
Figure 24. China Necrotizing Autoimmune Myositis Revenue, (US$, Mn), 2018-2030
Figure 25. Japan Necrotizing Autoimmune Myositis Revenue, (US$, Mn), 2018-2030
Figure 26. South Korea Necrotizing Autoimmune Myositis Revenue, (US$, Mn), 2018-2030
Figure 27. Southeast Asia Necrotizing Autoimmune Myositis Revenue, (US$, Mn), 2018-2030
Figure 28. India Necrotizing Autoimmune Myositis Revenue, (US$, Mn), 2018-2030
Figure 29. By Country - South America Necrotizing Autoimmune Myositis Revenue Market Share, 2018-2030
Figure 30. Brazil Necrotizing Autoimmune Myositis Revenue, (US$, Mn), 2018-2030
Figure 31. Argentina Necrotizing Autoimmune Myositis Revenue, (US$, Mn), 2018-2030
Figure 32. By Country - Middle East & Africa Necrotizing Autoimmune Myositis Revenue Market Share, 2018-2030
Figure 33. Turkey Necrotizing Autoimmune Myositis Revenue, (US$, Mn), 2018-2030
Figure 34. Israel Necrotizing Autoimmune Myositis Revenue, (US$, Mn), 2018-2030
Figure 35. Saudi Arabia Necrotizing Autoimmune Myositis Revenue, (US$, Mn), 2018-2030
Figure 36. UAE Necrotizing Autoimmune Myositis Revenue, (US$, Mn), 2018-2030
Figure 37. GlaxoSmithKline plc Necrotizing Autoimmune Myositis Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 38. Dr. Reddy's Laboratories Necrotizing Autoimmune Myositis Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 39. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Necrotizing Autoimmune Myositis Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 40. Hetero Drugs Limited Necrotizing Autoimmune Myositis Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 41. AbbVie Inc. Necrotizing Autoimmune Myositis Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Teva Pharmaceutical Industries Necrotizing Autoimmune Myositis Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Novartis AG Necrotizing Autoimmune Myositis Revenue Year Over Year Growth (US$, Mn) & (2018-2023)

Offer REPORT BUYING OPTIONS

USD GBP EURO YEN Single User Price
USD GBP EURO YEN Multi User Price
USD GBP EURO YEN Enterprise Price

---- OR ----

Frequently Asked Questions ?

  • Upto 24 hrs - Working days
  • Upto 48 hrs max - Weekends and public holidays
  • Single User License
    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License
    A license granted to multiple users.

  • Site License
    A license granted to a single business site/establishment.

  • Corporate License, Global License
    A license granted to all employees within organisation access to the product.
  • Online Payments with PayPal and CCavenue
  • Wire Transfer/Bank Transfer
  • Email
  • Hard Copy

Our Key Features

  • Data Accuracy and Reliability
  • Data Security
  • Customized Research
  • Trustworthy
  • Competitive Offerings
check discount